Richard D. Truesdell, Jr.

Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $750 million aggregate principal amount of 2.950% notes due 2029 and $1.25 billion aggregate principal…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation…

Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $45 million SEC-registered common stock and pre-funded warrants offering…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 46,000,000 shares of common stock of Plug Power Inc. for…

Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of an additional $500 million aggregate principal amount of its 4.000% senior notes due 2029. The…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,487,500 shares of common stock of…

Davis Polk advised the placement agents in connection with a private placement of shares of common stock of Applied Therapeutics, Inc. The aggregate proceeds of the private placement…

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…